A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to Entecavir

NCT04034368 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

8

Enrollment

OTHER

Sponsor class

Conditions

HBV

Interventions

DRUG: Tenofovir Alafenamide (TAF)

Sponsor

The First Hospital of Jilin University